FDA Approved: RYBREVANT FASPRO — Original Application (Janssen Biotech, Inc.)

View source ↗

Summary

FDA approved Rybrevant FASPRO, a subcutaneous co-formulation of amivantamab and hyaluronidase-lpuj, under an original application by Janssen Biotech. It is indi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Non-small Cell Lung Cancer with Egfr Exon 20 Insertion

Drugs mentioned

• RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj (human recombinant))

Snippet

ORIG AP for RYBREVANT FASPRO (AMIVANTAMAB AND HYALURONIDASE-LPUJ (HUMAN RECOMBINANT))